An advanced triple-secretagogue stack designed to maximally stimulate endogenous GH release through three complementary mechanisms. CJC-1295 extends GHRH signalling, Ipamorelin provides selective ghrelin-receptor stimulation with a clean side-effect profile, and GHRP-6 adds additional pulse amplitude alongside appetite stimulation. This combination is popular in performance communities seeking the highest attainable GH output without exogenous HGH.
Mechanism
Provides the sustained GHRH signal backbone of the stack, setting the hormonal stage for the additional secretagogues to stack upon by extending baseline GH pulse duration.
Adds selective ghrelin-receptor stimulation with a minimal side-effect profile, contributing to GH pulse amplitude without introducing meaningful cortisol or prolactin elevation.
Contributes additional GH pulse amplitude and appetite stimulation via ghrelin signalling, aimed at maximising total GH output; the appetite side effect can be a deliberate tool during caloric surplus phases.
Triple-pathway activation
CJC-1295 × Ipamorelin × GHRP-6
All three are unapproved research compounds. GHRP-6 commonly causes significant appetite stimulation and transient cortisol and prolactin elevation, distinguishing it from the cleaner side-effect profile of Ipamorelin. Risks overlap with chronically elevated GH: water retention, joint discomfort, and potential insulin resistance. Contraindicated in active or hormone-sensitive malignancies; no formal safety data exists for this triple combination.
Per-component source only — no combination study exists
Prolonged stimulation of GH and IGF-I secretion by CJC-1295
Ipamorelin, the first selective growth hormone secretagogue
On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone
A mitochondrial-targeted combination pairing two peptides with distinct but complementary mechanisms. MOTS-c enhances glucose metabolism and AMPK signaling while SS-31 (Elamipretide) stabilizes cardiolipin in the inner mitochondrial membrane, protecting against oxidative damage. Researched in contexts of aging, metabolic dysfunction, and exercise performance.
Both Thymalin and Epithalon are short bioregulatory peptides developed by Vladimir Khavinson and studied across decades of Russian gerontological research. Thymalin is associated with thymic peptide function and immune regulation in aging populations; Epithalon with pineal peptide activity, melatonin normalization, and telomere elongation. The combination is commonly referenced in longevity research for its dual immune-modulating and anti-aging mechanistic rationale.
AOD-9604, a C-terminal fragment of human growth hormone associated with selective lipolytic activity, is paired with Tirzepatide's dual GIP and GLP-1 receptor agonism for appetite regulation and energy balance. The combination is explored for addressing fat reduction through complementary peripheral and central mechanisms.
⚠ Educational Use OnlyPeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.
Free newsletter
The Peptide Research Digest
Weekly analysis on providers, sourcing and compounds — from the team behind PeptideBase.